CytoMed Therapeutics Total Current Liabilities

CytoMed Therapeutics (GDTC) currently reports a total current liabilities of $1.2M as of June 2026. That compares with $550K in the prior-year period — up 121.2% year over year. Use the charts on this page to explore CytoMed Therapeutics's total current liabilities history and peer comparisons.

CytoMed Therapeutics's total current liabilities increased from $550K to $1.2M — a 121.2% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

CytoMed Therapeutics reported $1.2M in total current liabilities as of June 2026. That compares with $550K in the prior-year period — up 121.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $1.2M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for CytoMed Therapeutics, and consider following GDTC for alerts when major investors trade the stock.